MFD

Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Retrieved on: 
星期三, 七月 6, 2022
American Society of Clinical Oncology, Decision-making, Patient, Research, Macrophage, GLOBE, Marketing, General officer, Progression-free survival, Phase, U.S. Securities and Exchange Commission, Tel Aviv University, Immune system, Animal, Oncology, Primary tumor, International Society, ASCO, Therapy, Security (finance), MFD, Department, FDA, Tuba City Regional Health Care Corporation, Annual general meeting, Tissue, TEL, Sheba Medical Center, Population, Risk, Newsweek, Immunotherapy, Sepsis, ORR, Cell, Technology, Private Securities Litigation Reform Act, Survival, Nasdaq, SOC, City, Ascites, Annual report, Abdomen, Surgical oncology, Metastasis, Cancer, Principal, Intraperitoneal injection, Human, Gene, Tumor microenvironment, Safety, Peritoneum, Society, Hope, Pharmaceutical industry, Medical imaging, Medical device

Patients with peritoneal metastases are in urgent need of novel treatment options, as standard-of-care (SOC) chemotherapy currently provides only modest survival benefits.

Key Points: 
  • Patients with peritoneal metastases are in urgent need of novel treatment options, as standard-of-care (SOC) chemotherapy currently provides only modest survival benefits.
  • We are eager to test this new combination with the hope of changing the lives of patients with peritoneal metastases.
  • We are excited to test this combination as a new hope for patients with peritoneal cancers.
  • It is designed to evaluate the safety and potential preliminary efficacy of Allocetra combined with SOC chemotherapy in patients with peritoneal metastases arising from solid cancer.

Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial

Retrieved on: 
星期四, 六月 16, 2022
Gy, MFD, Spinal cord, Lymphatic system, Cancer, Review, FDA, NDA, Safety, Ayub Ommaya, Perception, MTD, Company, Brain, U.S. Securities and Exchange Commission, Research, Fast Track, New Drug Application, PSTV, Disease, DNA, Liposome, Physician, Nasdaq, Radiation, SVP, Incidence, LM, Patient, White Light Rock & Roll Review, Toxic leukoencephalopathy, Communication, Neoplasm, Toxicity, Membrane, Accelerated approval (FDA), Therapy, Priority review, GLOBE, Meninges, Index (publishing), Pharmaceutical industry, Medical imaging

AUSTIN, Texas, June 16, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced the completion of enrollment in the first cohort of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM).

Key Points: 
  • We are pleased with initial response to the ReSPECT-LM trial by patients and physicians and the very early promising drug performance, said Norman LaFrance, M.D., Chief Medical Officer and SVP of Plus Therapeutics.
  • We intend to provide enrollment and complete clinical updates in the third quarter of 2022.
  • The ReSPECT-LM trial ( NCT05034497 ) is a multicenter, sequential cohort, open-label, single dose, dose escalation Phase 1/2a study using a modified Fibonacci 3+3 study design.
  • The primary endpoints of the study are the incidence and severity of adverse events/serious adverse events and dose limiting toxicities.

LBank Exchange Will List RTN on June 13, 2022

Retrieved on: 
星期六, 六月 11, 2022
Bitcoin, BSC, MFD, Sale, DEX, Defi, Decentralized finance, Non-fungible token, RTN, Cryptocurrency, Treaty of Dappes

Internet City, Dubai--(Newsfile Corp. - June 11, 2022) - LBank Exchange, a global digital asset trading platform, will list RTN on June 13, 2022.

Key Points: 
  • Internet City, Dubai--(Newsfile Corp. - June 11, 2022) - LBank Exchange, a global digital asset trading platform, will list RTN on June 13, 2022.
  • For all users of LBank Exchange, the RTN/USDT trading pair will be officially available for trading at 18:00 (UTC+8) on June 13, 2022.
  • The RTN token will be listed on LBank Exchange at 18:00 (UTC+8) on June 13, 2022, to further expand its global reach and help it achieve its vision.
  • The RTN token will be listed on LBank Exchange at 18:00 (UTC+8) on June 13, 2022, investors who are interested in RTN investment can easily buy and sell it on LBank Exchange by then.

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Retrieved on: 
星期四, 六月 9, 2022
Research, General Health, Pharmaceutical, Oncology, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, FDA, Other Science, Health, Goal, Time, Thalassemia, LVV, Survival, White matter, HLA, Brain, SUSAR, Review, BLA, Thought, Vomiting, National Medical Products Administration, Health, View, Graft-versus-host disease, U.S. Securities and Exchange Commission, Breakthrough therapy, Food, Forward-looking statement, Bluebird, Male, Sickle cell disease, Industry, Communication, ELL, Biologics license application, Pancytopenia, Gene, Nausea, Security (finance), Neurodegeneration, Bird, HSC, Patient, PDUFA, Sumathi Best Television Current Reporting Award, Disorder, Lists of diseases, CALD, Bluebird bio, Private Securities Litigation Reform Act, MFD, Lentivirus, Research, Disease, MDS, Spinal cord, FDA, Mortality, Stem cell, Risk, Myelodysplastic syndrome, Adverse effect, ALD, Overalls, Death, Safety, Pharmaceutical industry, ABCD1

On the question Do the benefits of eli-cel outweigh the risks, for the treatment of any sub-population of children with early active cerebral adrenoleukodystrophy (CALD)?

Key Points: 
  • On the question Do the benefits of eli-cel outweigh the risks, for the treatment of any sub-population of children with early active cerebral adrenoleukodystrophy (CALD)?
  • We are grateful to the families, clinicians and committee members who participated in todays advisory committee discussion and remain committed to working with the FDA as it completes its review of the eli-cel Biologics License Application.
  • In addition to granting eli-cel BLA priority review, the FDA previously granted eli-cel Orphan Drug status, Rare Pediatric Disease designation, and Breakthrough Therapy designation.
  • Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the worldsetting the standard for industry.

bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting

Retrieved on: 
星期二, 六月 7, 2022
Health, FDA, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Goal, Company, LVV, Survival, Safety, Blas, Leukopenia, Review, ABCD1, Vomiting, National Medical Products Administration, Thrombocytopenia, Health, View, Graft-versus-host disease, U.S. Securities and Exchange Commission, Food, Forward-looking statement, Bluebird, Prescription Drug User Fee Act, RBC, Sickle cell disease, Industry, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Communication, Pancytopenia, Gene, Betibeglogene autotemcel, Nausea, Abdominal pain, Security (finance), Bird, Phase 3, Patient, PDUFA, Sumathi Best Television Current Reporting Award, BEH, CALD, Bluebird bio, Private Securities Litigation Reform Act, Cytopenia, MFD, Adult, Research, HB, Tachycardia, Disease, BB305, Neutropenia, FDA, Stem cell, Risk, Myelodysplastic syndrome, NASDAQ, SAE, ALD, Death, Breathe Me, Pharmaceutical industry, Vaccine

The advisory committee meeting will take place June 9-10, 2022.

Key Points: 
  • The advisory committee meeting will take place June 9-10, 2022.
  • The Company is not responsible for the content of, nor the statements made in, the briefing materials that were prepared by the FDA.
  • bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.
  • bluebird bio is a trademark of bluebird bio, Inc.

Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Retrieved on: 
星期一, 六月 6, 2022
Human, MFD, Immunotherapy, Macrophage, Company, Society, Marketing, Gene, Tams, Survival, Safety, Neoplasm, Decision-making, ORR, Progression-free survival, Animal, Metastasis, Annual report, Security (finance), International Society, Cancer, U.S. Securities and Exchange Commission, MOH, Cell, Nasdaq, Ovarian cancer, Medicine, Ministry, Peritoneum, FDA, Therapy, GLOBE, Patient, Primary tumor, Private Securities Litigation Reform Act, Sepsis, Intraperitoneal injection, Trial of the century, Ascites, Risk, Immune system, Phase, Immunosuppression, Population, SOC, Tissue, Mission statement, Pharmaceutical industry, Medical imaging, Medical device

Nes-Ziona, Israel, June 06, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today announced that the Israeli Ministry of Health (MOH) authorized the initiation of a company-sponsored Phase I/II clinical trial evaluating Allocetra™ combined with chemotherapy in patients with peritoneal metastases arising from solid cancer.

Key Points: 
  • Patients with peritoneal metastases are in urgent need of novel treatment options, as standard-of-care (SOC) chemotherapy provides only modest survival benefits.
  • It is designed to evaluate the safety and potential preliminary efficacy of Allocetra combined with SOC chemotherapy in patients with peritoneal metastases arising from solid cancer.
  • Intraperitoneally delivered Allocetra and SOC chemotherapy administered via PIPAC will be given to patients every six weeks.
  • Enlivex plans to initiate the Phase I/II trial evaluating Allocetra in combination with chemotherapy in patients with peritoneal metastases arising from solid cancer in Q3 2022.

Garmin delivers 750th integrated flight deck upgrade for King Air aircraft

Retrieved on: 
星期三, 五月 18, 2022
Technology, Mobile, Wireless, Aerospace, Manufacturing, Public Policy, Government, Air, Defense, Transport, Other Defense, Software, Contracts, White House, Federal Government, Hardware, Data Management, GRMN, Information International, Inc., HSI, Social media, Army of the United States, U.S. Securities and Exchange Commission, Investment, Form 10-K, Solution, PFD, IFF, Government, Aviation, B200, Aircraft, ESP, Adventure, Defense, Commission, Marketing, United Kingdom, 750th Bombardment Squadron, Forward-looking statement, Beechcraft King Air, GPS, Risk, STC, Security (finance), MFD, SVT, Supplemental type certificate, NYSE, Annual report, Airline, Satellite navigation device, United States Army, G1000, Garmin, Newsroom

Garmin International, Inc., a unit of Garmin Ltd. (NYSE: GRMN), today celebrated the delivery of its 750th G1000/G1000 NXi integrated flight deck upgrade for King Air aircraft.

Key Points: 
  • Garmin International, Inc., a unit of Garmin Ltd. (NYSE: GRMN), today celebrated the delivery of its 750th G1000/G1000 NXi integrated flight deck upgrade for King Air aircraft.
  • This upgrade allows the U.S. Army to take advantage of the scalable G1000 NXi platform, including the new mission-specific capabilities recently certified for the King Air G1000 NXi upgrade.
  • The global acceptance of the G1000/G1000 NXi King Air upgrade has made it the most successful integrated flight deck retrofit for this family of aircraft, said Carl Wolf, Garmin vice president of aviation sales and marketing.
  • We look forward to continuing to grow the success of the G1000 NXi integrated flight deck retrofit in the King Air cockpit to even more owners and operators around the world.

Macquarie/First Trust Global Infrastructure/Utilities Dividend & Income Fund Declares its Quarterly Distribution of $0.20 Per Share

Retrieved on: 
星期二, 五月 10, 2022
Professional Services, Finance, Internal Revenue Code section 409A, COVID-19, Weather, Federal Energy Regulatory Commission, ERISA, Internal Revenue Code, Investment, MAM, Adviser, FINRA, MLP, Capital gain, Union, Fund, Policy, FTA, NYSE, NAV, AIB (NI), Instability, Judgement, Respiratory disease, Macquarie Group, New York Stock Exchange, London Interbank Bid Rate, Core Component Technical Specification, United, Terrorism, FERC, FTP, Risk, Debt-to-GDP ratio, LIBOR, Asset-backed security, Vaccine, Movement, Income, Loss, Disease, MFD, Infection, Technology, Ownership, Hedge fund, Natural Resources, Acquisition, Renewable energy, Life insurance, Security (finance), Financial adviser, Financial services, Bank, Brexit

Macquarie/First Trust Global Infrastructure/Utilities Dividend & Income Fund (the "Fund") (NYSE: MFD) has declared the Fund's regularly scheduled quarterly distribution of $0.20 per share.

Key Points: 
  • Macquarie/First Trust Global Infrastructure/Utilities Dividend & Income Fund (the "Fund") (NYSE: MFD) has declared the Fund's regularly scheduled quarterly distribution of $0.20 per share.
  • First Trust Advisors L.P. ("FTA") is a federally registered investment advisor and serves as the Fund's investment advisor.
  • FTA and its affiliate First Trust Portfolios L.P. ("FTP"), a FINRA registered broker-dealer, are privately-held companies that provide a variety of investment services.
  • FTP is also a distributor of mutual fund shares and exchange-traded fund creation units.

Garmin quatix 7 smartwatch fuels the active boater lifestyle

Retrieved on: 
星期四, 四月 28, 2022
Technology, Mobile, Wireless, Sports, Water Skiing, Fishing, Yachting, Sailing, Powerboating, Consumer Electronics, Life, NYSE, U.S. Securities and Exchange Commission, GHC, Weather, Music, Information International, Inc., AMOLED, Deezer, Commission, Wind, Water, Electronics, Wrist, Forward-looking statement, Risk, United Kingdom, Golf, Mark (given name), Amazon Music, Multimedia, Diagnosis, Annual report, RPM, GRMN, Multi, Security (finance), Respiration, Friends, Titanium, Skiing, MFD, Darkness, 7 series, Health, GNX, Form 10-K, Video game console, Satellite navigation device, Fusion, Sapphire, Garmin

Complete with 3 models quatix 7, quatix 7 Sapphire and quatix 7X Solar the full series includes Garmins flagship smartwatch and boating features with added functionality and premium features available for high-end editions.

Key Points: 
  • Complete with 3 models quatix 7, quatix 7 Sapphire and quatix 7X Solar the full series includes Garmins flagship smartwatch and boating features with added functionality and premium features available for high-end editions.
  • Whether boating, sailing or fishing, the quatix 7 Series offers the advantage of seamless integration with Garmin chartplotters and other marine electronics2.
  • The quatix 7, quatix 7 Sapphire and quatix 7X Solar are available now with suggested retail prices ranging from $699.99 to $1,199.99.
  • Garmin, quatix, Fusion, BlueChart, and GPSMAP are registered trademarks and LakeV, Body Battery, Garmin Pay, SkiView, GHC and GNX are trademarks of Garmin Ltd. or its subsidiaries.

Dialyze Direct Publishes Noteworthy Post-Dialysis Recovery Time Findings in ‘Hemodialysis International’

Retrieved on: 
星期二, 四月 26, 2022
Nursing, Health, Hospitals, Practice Management, Managed Care, General Health, Patient, Directorate of Research and Civil Affairs, Population health, Population, Nephrology, General number field sieve, Health, Nathan W. Levin, Rehabilitation, SNF, CNN, Hypotension, DRT, ESRD, Chronic kidney disease, MSN, Dialysis, Mortality, Technology, MFD, Direct, Albert Einstein College of Medicine, Kidney disease, Bureau of Oceans and International Environmental and Scientific Affairs, DTR, Solution, Method, Mercury (element), Epidemiology, Quality of life, Senior, RN, Overalls, Internal medicine, Health insurance, Medicine, Research

With conventional dialysis, nursing home patients typically require a prolonged period of time to recover from the effects of each dialysis treatment.

Key Points: 
  • With conventional dialysis, nursing home patients typically require a prolonged period of time to recover from the effects of each dialysis treatment.
  • Our findings in this patient population receiving more frequent dialysis show patients are able to participate in activities much sooner post-dialysis, said Alice Hellebrand, chief nursing officer and senior vice president at Dialyze Direct and a co-author of the article.
  • Founded in 2015, Dialyze Direct is a leading kidney care innovation company that seeks breakthrough solutions for patients suffering from kidney disease.
  • Dialyze Direct currently operates in 13 states with new operations launching soon in additional states.